Internal Server Error

TeneoBio - About the company

TeneoBio is an acquired company based in Menlo Park (United States), founded in 2007 by Roland Buelow. It operates as a Developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases. TeneoBio has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 2051 active competitors, including 449 funded and 322 that have exited. Its top competitors include companies like Antheia, Synthego and Axol Bioscience.

Company Details

TeneoBio is a developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases. It is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies as therapeutics against multiple diseases. It has several products in pre-clinical development for the treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. Its antibody discovery engine is based on UniRat, a proprietary heavy chain only, human immunoglobulin transgenic. They apply a novel sequence-based discovery approach using NGS, bioinformatics, and high-throughput recombinant protein expression.
Email ID
*****@teneobio.com
Registered Address
Menlo Park, California
Key Metrics
Founded Year
2007
Location
Menlo Park, United States
Stage
Acquired
Last Known Valuation
$***** as on Jul 28, 2021
Ranked
Employee Count
50 - 199 as on Mar 01, 2026
Similar Companies
Exit Details
Acquired by Amgen (Jul 27, 2021)

TeneoBio's acquisition details

TeneoBio got acquired by Amgen on Jul 27, 2021 at an acquisition amount of $*****.
Click here to take a look at TeneoBio's acquisition in detail
Sign up to download TeneoBio's company profile

TeneoBio's funding and investors

TeneoBio has raised funding over 5 rounds. Its first funding round was on Mar 01, 2018. Its latest funding round was a Grant (prize money) round on Sep 01, 2020 for $*****. 1 investor participated in its latest round. TeneoBio has 2 institutional investors.

Here is the list of recent funding rounds of TeneoBio:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Sep 01, 2020
4197145
Grant (prize money)
8254533
8786440
6033997
4639054
Sep 19, 2019
2614386
Grant (prize money)
3304470
9069345
8395823
Aug 12, 2019
2793836
Grant (prize money)
9060526
3929055
6600807
lockAccess funding benchmarks and valuations. Sign up today!

TeneoBio's founders and board of directors

Founder? Claim Profile
The founders of TeneoBio is Roland Buelow.
Here are the details of TeneoBio's key team members:

TeneoBio's employee count trend

TeneoBio has 50 - 199 employees as of Mar 26. Here is TeneoBio's employee count trend over the years:
Employee count trend for TeneoBio
lockUncover TeneoBio's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

TeneoBio's Competitors and alternates

Top competitors of TeneoBio include Antheia, Synthego and Axol Bioscience. Here is the list of Top 10 competitors of TeneoBio, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Antheia
Antheia
2013, Palo Alto (United States), Series C
Genetically engineered yeast cells to produce medicinal products
$176M
68/100
2nd
Logo for Synthego
Synthego
2012, Redwood City (United States), Acquired
Manufacturer of custom CRISPR gene editors and molecular biology reagents
$460M
67/100
3rd
Logo for Axol Bioscience
Axol Bioscience
2013, Cambridge (United Kingdom), Series A
Provider of human cells, reagents, and reprogramming services
$13.3M
65/100
4th
Logo for Akeso
Akeso
2012, Zhongshan (China), Public
Developer of antibody drug conjugates for the treatment of broad spectrum diseases
$195M
65/100
5th
Logo for Novogene Corporation
Novogene Corporation
2011, Beijing (China), Series B
Provider of genomic services and solutions
$75M
64/100
6th
Logo for Korro Bio
Korro Bio
2018, Cambridge (United States), Public
Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases
$4M
64/100
7th
Logo for Avalyn Pharma
Avalyn Pharma
2011, Seattle (United States), Public
Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis
$389M
63/100
8th
Logo for enGene
enGene
1999, Saint laurent (Canada), Public
Developer of oral non-viral gene therapy platform
$54M
63/100
9th
Logo for Watchmaker Genomics
Watchmaker Genomics
2018, Boulder (United States), Series A
Developer of gene-editing technology
$48.3M
63/100
10th
Logo for One Biosciences
One Biosciences
2020, Paris (France), Series A
Developer of single-cell therapeutics solutions to treat multiple health disorders
$22.4M
63/100
134th
Logo for TeneoBio
TeneoBio
2007, Menlo Park (United States), Acquired
Developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases
-
48/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on TeneoBio's competitors? Click here to see the top ones

TeneoBio's Investments and acquisitions

TeneoBio has made no investments or acquisitions yet.

Reports related to TeneoBio

Here is the latest report on TeneoBio's sector:

News related to TeneoBio

lockFilter this list
•
Amgen Successfully Completes Acquisition Of Teneobio, Inc.Investing News•Oct 19, 2021•Amgen, TeneoBio
•
AbbVie to acquire TeneoOne from TeneobioPharmaceutical Technology•Jun 25, 2021•AbbVie, TeneoBio
•
Kite licences Teneobio’s multiple myeloma targeting antibodiesPharmaceutical Technology•Apr 03, 2020•Kite Pharma, TeneoBio, Gilead
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about TeneoBio

Explore our recently published companies
  • Jai Dadi Group - Kolkata based, 1983 founded, Unfunded company
  • Ronda - Lausen based, 1946 founded, Public company
  • YUKE - Krefeld based, 1989 founded, Public company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford